贝瑞基因(000710) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥217,759,068.08, a decrease of 22.08% compared to ¥279,476,530.07 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥6,462,206.12, representing a decline of 178.47% from a profit of ¥8,235,122.95 in the previous year[5] - Total operating revenue for the current period was ¥217,759,068.08, a decrease of 22.14% compared to ¥279,476,530.07 in the previous period[18] - Net profit for the current period was a loss of ¥5,639,720.43, compared to a profit of ¥9,419,004.86 in the previous period, representing a significant decline[19] - The total comprehensive income for the current period was -¥6,454,024.62, compared to ¥9,482,565.46 in the previous period, indicating a significant downturn[20] Cash Flow - The net cash flow from operating activities improved by 19.03%, with a net outflow of ¥34,593,391.26 compared to ¥42,721,485.35 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥34,593,391.26, an improvement from the previous period's outflow of ¥42,721,485.35[21] - Cash inflow from financing activities was $26,700,000, while cash outflow was $16,023,617.06, leading to a net cash flow of $10,676,382.94[22] - The cash flow from financing activities showed a net inflow of ¥10,676,382.94, a turnaround from a net outflow of ¥40,844,341.78 in the previous year[9] - Net cash inflow from investment activities totaled $2,222,300, while cash outflow was $14,782,979.97, resulting in a net cash flow of -$12,560,679.97[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,421,243,616.28, an increase of 1.53% from ¥2,384,723,994.06 at the end of the previous year[5] - The total liabilities increased to ¥717,508,200.85, up from ¥669,562,176.39, indicating a rise of 7.03%[16] - The company has a significant increase in lease liabilities from 43,238,080.56 CNY to 133,833,850.08 CNY, an increase of approximately 209.5%[15] - The company's total current assets decreased from 1,439,086,278.92 CNY to 1,384,255,362.80 CNY, a reduction of approximately 3.8%[13] - Total current liabilities decreased from 590,556,621.16 CNY to 547,957,993.91 CNY, a reduction of about 7.2%[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 63,808[11] - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.45% of shares, totaling 44,002,000 shares, which are pledged and frozen[11] Earnings and Expenses - The company reported a basic earnings per share of -¥0.02, down 200.00% from ¥0.02 in the same period last year[5] - The weighted average return on equity was -0.39%, a decrease of 0.83% compared to 0.44% in the previous year[5] - Research and development expenses increased to ¥21,653,803.47, up from ¥20,699,969.47, reflecting a growth of 4.6%[18] - The basic earnings per share for the current period was -¥0.02, compared to ¥0.02 in the previous period[20] Other Information - The company recorded a significant increase in receivables, with notes receivable rising by 46.94% to ¥3,801,600.00 from ¥2,587,200.00[9] - The company has not reported any new product developments or market expansion strategies in the current call[12] - The first quarter report for 2025 was not audited, indicating preliminary financial results[23] - The investment income increased by 134.05%, amounting to ¥954,578.63 compared to a loss of ¥2,803,568.59 in the previous year[9]